Genmab CEO eyes big opportunities in global biotech downswing
New guidelines from the US Food and Drug Administration and the continued downswing within the biotech industry at large provide a range of new opportunities for Danish biotech firm Genmab, says CEO Jan van de Winkel.
by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
The global biotech industry’s battering on the stock market in recent months doesn’t have to be all bad news, says Jan van de Winkel, the CEO of Danish biotech firm Genmab, which has also been impacted on the stock exchange.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
